Skip to main content

Advancing Progress in the Development of Combination Cancer Therapies with Immune Checkpoint Inhibitors Proceedings of a Workshop (2019) / Chapter Skim
Currently Skimming:

Appendix A: Statement of Task
Pages 61-62

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 61...
... • The assessment of safety and efficacy/clinical benefit in clinical trials. • Innovations in clinical development programs for combination treatment strategies, such as approaches for prioritizing potential combinations (including multimodal therapy)
Read the entire page →
From page 62...
... 62 CANCER THERAPIES WITH IMMUNE CHECKPOINT INHIBITORS The committee will develop the agenda for the workshop sessions, select and invite speakers and discussants, and moderate the discussions. A proceedings of the presentations and discussions at the workshop will be prepared by a designated rapporteur in accordance with institutional guidelines.
Read the entire page →

Key Terms

  • clinical development
  • multimodal therapy
  • preclinical modeling
  • identify promising
  • facilitating access

  • prioritizing potential
  • promising combinations
  • treatment strategies
  • evidence requirements
  • drug candidates

  • combination trials
  • including multimodal
  • combination treatment
  • including precompetitive
  • clinical trials

  • drug development
  • treatment response
  • information exchange
  • potential combinations
  • diagnostic industries

  • biomarkers predictive
  • precompetitive collaboration
  • development programs
  • regulatory evaluation


    • This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
    More information on Chapter Skim is available.